{"nct_id":"NCT01225731","title":"A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)","status":"COMPLETED","status_verified_date":"2019-01","start_date":"2010-10-25","start_date_type":"ACTUAL","primary_completion_date":"2011-11-04","primary_completion_date_type":"ACTUAL","completion_date":"2012-10-24","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["MRK"]}